To synthesize current understanding of IL-5 biology and evaluate clinical trial evidence for IL-5/IL-5Rα-targeted biologics across major eosinophilia-associated diseases, highlighting its significance.
Key Findings:
Mepolizumab is effective in reducing asthma exacerbations, nasal polyp burden, EGPA relapse activity, and HES flares, with specific data points.
Reslizumab improves exacerbation rates and lung function in SEA, with quantifiable results.
Benralizumab induces rapid eosinophil depletion and reduces exacerbation rates and corticosteroid use in SEA and EGPA, supported by data.
Depemokimab offers long-acting IL-5 inhibition and improves outcomes in SEA and CRSwNP, with evidence of efficacy.
Safety profiles of these biologics are generally reassuring with mild to moderate adverse events, supported by trial data.
Interpretation:
The IL-5/IL-5Rα pathway is a critical therapeutic target in eosinophilia-related disorders, with multiple biologics demonstrating clinical effectiveness and manageable safety profiles, impacting clinical practice.
Limitations:
Potential incomplete suppression of tissue eosinophils due to alternative cytokine pathways, including GM-CSF and IL-3.
Need for further research to address remaining evidence gaps, including long-term effects and patient variability.
Conclusion:
The review highlights the transformative role of IL-5/IL-5Rα inhibitors in managing eosinophilia-related diseases and emphasizes the need for ongoing research to fully understand their impact.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
